WETTIG THANE (Chief Commercial Officer) purchased 17.4% of their position (3.70K shares) of KYNTRA BIO, INC. on the open market
Open‑market purchase worth $33.7K — a significant purchase. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 11/17/2025ACC: 0001815638-25-000004
Officer· Chief Commercial Officer
Since Jun 2020
+3.70K
Net shares
Net buyer
$33.7K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
3.70K acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+1K
Price / share
$9.18
Trade value
$9.18K
% of position
4.7%
11/13/2025
21.24K→22.24K
Common Stock
Direct
Shares
+2.70K
Price / share
$9.10
Trade value
$24.57K
% of position
12.1%
11/17/2025
22.24K→24.94K
Total
Net shares
+3.70K
Net value
$33.75K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 11/13/2025 | P · Purchase | +1K | $9.18 | $9.18K | 4.7% | 21.24K | 22.24K |
| Common Stock Direct | 11/17/2025 | P · Purchase | +2.70K | $9.10 | $24.57K | 12.1% | 22.24K | 24.94K |
| Total | +3.70K | $33.75K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned40.00
Total
40.00 indirect40.00
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 40.00 | Indirect |
| Total | 40.00 | 40.00 indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported